Table 1

Recommendations of professional organisations in terms of communicating about prostate screening

Items included in recommendation and guidanceProfessional organisation
Is GP advised about whether to raise the topic with men if men do not raise it first?
Is a decision aid recommended?
Is a decision aid provided?
Is IDM* recommended?
Is SDM† recommended?
Is guideline accompanied by a clinician information sheet?‡
Is guideline accompanied by a patient information sheet?§
Does guideline recommend clinician to share their own PSA screening decision?
Consider medico-legal responsibilities?
  • *The patient is presented with all the information pertinent to making a decision and then assumes final authority for the decision.30

  • †The patient is provided with all the relevant information and works with the healthcare provider to reach a decision that reflects the health preference of the patient.30

  • ‡A clinician information sheet is a fact sheet summarising the evidence of benefits, limitations and associated risks of prostate screening to help clinicians to accurately inform men.

  • §A patient information sheet is a fact sheet outlining the benefits, limitations and associated risks of having a PSA test for prostate cancer risk.

  • ACS, American Cancer Society; AUA, American Urological Association; GP, general practitioner; IDM, informed decision making; NCI, National Cancer Institute of the National Institutes of Health; NHMRC, National Health and Medical Research Council; NHS/PHE, National Health Service/Public Health England; NICE,  National Institute for Health and Care Excellence; PCFA/CCA, Prostate Cancer Foundation of Australia/Cancer Council Australia; PSA, prostate-specific antigen; RACGP, Royal Australian College of General Practitioners; SDM, shared decision making; USANZ, Urological Society of Australia and New Zealand; USPSTF, United States Preventive Services Task Force.